Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sirolimus versus mycophenolate mofetil
- Development stage
- Unknown
- Lead developer
- EUROSPK Study Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This entry refers to a clinical trial comparison conducted by the EUROSPK Study Group evaluating two immunosuppressive regimens in patients undergoing simultaneous pancreas-kidney (SPK) transplantation. The study compared a regimen based on sirolimus (an mTOR inhibitor) against one based on mycophenolate mofetil (an IMPDH inhibitor), both used in combination with tacrolimus, induction therapy with polyclonal antibodies, and short-term corticosteroids. The primary goal was to assess the efficacy in preventing graft rejection and the safety profiles of these combinations in type 1 diabetic recipients with end-stage renal disease. Sirolimus (Rapamune) acts by inhibiting the mammalian target of rapamycin (mTOR) to block T-cell proliferation, while mycophenolate mofetil (CellCept) inhibits inosine monophosphate dehydrogenase (IMPDH) to suppress lymphocyte purine synthesis.
- Brand names
- RapamuneCellCeptPrograf
- Other names
- EUROSPK StudySirolimus vs MMF in SPK Transplantationsirolimus versus mycophenolate mofetil-EUROSPK Study Group-graft rejection
02
Targets
IMPDH (Inosine-5'-monophosphate dehydrogenase 1)mTOR (Mammalian target of rapamycin kinase)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on sirolimus versus mycophenolate mofetil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sirolimus versus mycophenolate mofetil.